Global Sunitinib malate market to reach XX by 2027. Global Sunitinib malate market is valued at approximately XX in 2020 and is anticipated to grow with a healthy growth rate of more than XX over the forecast period 2021-2027. Sunitinib malate is a small-molecule medication that has been shown to block several tyrosine kinases in different receptors (RTKs). Sunitinib is recognized as an effective drug in suppressing cell proliferation and angiogenesis due to its potential antineoplastic action. Sunitinib capsules are used to treat pancreatic neuroendocrine tumors, renal cancer, and gastrointestinal stromal tumors (GIST). Sunitinib was the first cancer treatment to be licensed for two indications at the same time: renal cell carcinoma and imatinib-resistant gastrointestinal stromal tumor (GIST). The global sunitinib malate market is primarily driven by technological advancements and the rising prevalence of pancreatic cancer. Pancreatic cancer's rising prevalence is a primary driver of the worldwide sunitinib capsules market. According to the American Cancer Society, over 56,000 Americans will be diagnosed with pancreatic cancer in 2017, with over 42,000 of them anticipated to die by pancreatic cancer. Pancreatic tumors are more difficult to diagnose and remove than other tumors due to their relative inaccessibility. As a result, sunitinib malate capsules are increasingly being used to treat pancreatic cancers. However, higher cost of research and development(R&D), and high cost of sutent may impede market growth over the forecast period of 2021-2027.

The regional analysis of the global Sunitinib malate market is considered for the key regions such as North America Asia Pacific, , Latin America, Europe, and Rest of the World (ROW). North America is the leading region across the world in terms of market share due to rising prevalence of pancreatic cancer in the region. Whereas Asia Pacific is also anticipated to exhibit the highest growth rate over the forecast period 2021-2027, due to growing awareness about pancreatic cancer in developing economies such as India, China, and others.
Major market player included in this report are:

Pfizer Incorporation
Topcarepharm
Njfirstpharm
J&K Scientific
Targetmol
Synthland Ltd
Teva Pharmaceutical Industries Ltd.
Astellas Pharma, Inc.
Dendreon Corporation
Ferring Pharmaceuticals, Inc.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type:
Purity: >99%
Purity: >98%
Purity: >97%
By Application:
Pancreatic Neuroendocrine Tumors
Kidney Cancer
Gastrointestinal stromal tumor
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2017, 2018-19
Base year - 2019-2020
Forecast period - 2021 to 2027.

Target Audience of the Global Sunitinib malate market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors